Pharmaceuticals, Biotechnology and Life Sciences
Alvogen announced today the completion of the sale of its Central and Eastern European (CEE) business to Zentiva for an undisclosed value. The sale of the company’s CEE platform includes over 200 generic and over-the-counter products across multiple therapeutic areas and covering 14 key markets.
Alvogen is selling its Central and Eastern European business to Zentiva, for an undisclosed amount, to focus on developing other areas, with the transaction to be closed in first quarter of 2020.
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the…
Sanofi has gotten an offer from Advent International, a global investor in healthcare sector, for purchase of Zentiva, Sanofi’s European…